Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32901
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSTESSEL, Bjorn-
dc.contributor.authorVancuchelen, Charlotte-
dc.contributor.authorBRUCKERS, Liesbeth-
dc.contributor.authorGeebelen, Laurien-
dc.contributor.authorCALLEBAUT, Ina-
dc.contributor.authorVANDENBRANDE, Jeroen-
dc.contributor.authorPallens, Ben-
dc.contributor.authorVan Tornout, Michiel-
dc.contributor.authorOry, Jean-Paul-
dc.contributor.authorvan Halem, Karlijn-
dc.contributor.authorMESSIAEN, Peter-
dc.contributor.authorHERBOTS, Lieven-
dc.contributor.authorRamaekers, Dirk-
dc.contributor.authorDubois, Jasperina-
dc.date.accessioned2020-12-14T09:53:50Z-
dc.date.available2020-12-14T09:53:50Z-
dc.date.issued2020-
dc.date.submitted2020-11-24T12:51:43Z-
dc.identifier.citationThrombosis Research, 194 , p. 209 -215-
dc.identifier.issn0049-3848-
dc.identifier.urihttp://hdl.handle.net/1942/32901-
dc.description.abstractIntroduction: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. Methods: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups. Results: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group. Conclusion: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. .-
dc.description.sponsorshipThis study is part of the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital.-
dc.language.isoen-
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD-
dc.rights2020 Elsevier Ltd. All rights reserved-
dc.subject.otherCOVID-19-
dc.subject.otherThromboprophylaxis-
dc.subject.otherVenous thromboembolism-
dc.subject.otherMortality-
dc.subject.otherContinuous renal replacement therapy-
dc.titleImpact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study-
dc.typeJournal Contribution-
dc.identifier.epage215-
dc.identifier.spage209-
dc.identifier.volume194-
local.format.pages7-
local.bibliographicCitation.jcatA1-
dc.description.notesStessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium.-
dc.description.notesbjorn.stessel@jessazh.be-
dc.description.otherStessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium. bjorn.stessel@jessazh.be-
local.publisher.placeTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.thromres.2020.07.038-
dc.identifier.pmid32788120-
dc.identifier.isiWOS:000568490100037-
dc.contributor.orcidCallebaut, Ina/0000-0002-6666-6783-
dc.identifier.eissn1879-2472-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Stessel, Bjorn; Vancuchelen, Charlotte; Geebelen, Laurien; Callebaut, Ina; Vandenbrande, Jeroen; Pallens, Ben; Van Tornout, Michiel; Ory, Jean-Paul; Dubois, Jasperina] Jessa Hosp, Dept Intens Care & Anesthesiol, Hasselt, Belgium.-
local.description.affiliation[Stessel, Bjorn; Callebaut, Ina; Messiaen, Peter] UHasselt, Fac Med & Life Sci, LCRC, B-3590 Diepenbeek, Belgium.-
local.description.affiliation[Geebelen, Laurien] Hasselt Univ, Data Sci Inst, I BioStat, Martelarenlaan 42, B-3500 Hasselt, Belgium.-
local.description.affiliation[van Halem, Karlijn; Messiaen, Peter] Jessa Hosp, Dept Infect Dis & Immun, Hasselt, Belgium.-
local.description.affiliation[Herbots, Lieven] Jessa Hosp, Dept Cardiol, Hasselt, Belgium.-
local.description.affiliation[Herbots, Lieven] Jessa Hosp, Coronary Care Unit, Hasselt, Belgium.-
local.description.affiliation[Ramaekers, Dirk] Jessa Hosp, Hasselt, Belgium.-
local.description.affiliation[Ramaekers, Dirk] Univ Leuven, Leuven Inst Healthcare Policy LIHP, Leuven, Belgium.-
local.uhasselt.internationalno-
item.contributorSTESSEL, Bjorn-
item.contributorVancuchelen, Charlotte-
item.contributorBRUCKERS, Liesbeth-
item.contributorGeebelen, Laurien-
item.contributorCALLEBAUT, Ina-
item.contributorVANDENBRANDE, Jeroen-
item.contributorPallens, Ben-
item.contributorVan Tornout, Michiel-
item.contributorOry, Jean-Paul-
item.contributorvan Halem, Karlijn-
item.contributorMESSIAEN, Peter-
item.contributorHERBOTS, Lieven-
item.contributorRamaekers, Dirk-
item.contributorDubois, Jasperina-
item.fullcitationSTESSEL, Bjorn; Vancuchelen, Charlotte; BRUCKERS, Liesbeth; Geebelen, Laurien; CALLEBAUT, Ina; VANDENBRANDE, Jeroen; Pallens, Ben; Van Tornout, Michiel; Ory, Jean-Paul; van Halem, Karlijn; MESSIAEN, Peter; HERBOTS, Lieven; Ramaekers, Dirk & Dubois, Jasperina (2020) Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. In: Thrombosis Research, 194 , p. 209 -215.-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
item.validationecoom 2021-
crisitem.journal.issn0049-3848-
crisitem.journal.eissn1879-2472-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S0049384820303297-main.pdfPublished version558.17 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.